ValuEngine Downgrades BiondVax Pharmaceuticals (BVXV) to Sell

ValuEngine lowered shares of BiondVax Pharmaceuticals (NASDAQ:BVXV) from a hold rating to a sell rating in a research report report published on Friday.

Shares of BiondVax Pharmaceuticals (BVXV) opened at $5.42 on Friday. BiondVax Pharmaceuticals has a 52 week low of $3.04 and a 52 week high of $10.75.

TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/05/valuengine-downgrades-biondvax-pharmaceuticals-bvxv-to-sell.html.

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about BiondVax Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BiondVax Pharmaceuticals Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit